Targeting glycolytic pathway enzymes, such as glucose transporter (GLUT), hexokinase (HK), pyruvate kinase M2 (PKM2), and lactate dehydrogenase-A (LDHA), the first and rate-limiting of the pentose phosphate pathway (PPP) enzyme glucose-6-phosphate dehydrogenase (G6PD), and the fatty acid biosynthesis pathway enzyme fatty acid synthesis (FASN), may overcome cancer drug resistance in cancer cells (Zhou et al., 2010; Catanzaro et al., 2015). This evidence concerns the gene SLC2A1 and cancer.